Table of Contents
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. United States Solid Tumor Testing Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Increasing prevalence of cancer
3.2.1.2. Rising awareness of early detection
3.2.1.3. Growing adoption of personalized medicines
3.2.2. Restraints
3.2.2.1. Limited access to testing
3.2.2.2. Lack of standardization
3.2.3. Opportunities
3.2.3.1. Technological advancements
3.2.3.2. Rising healthcare expenditure coupled with increased insurance coverage
3.2.4. Challenges
3.2.4.1. Reimbursement issues
3.3. Technology Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. United States Solid Tumor Testing Market Overview
4.1. Market Size & Forecast, 2019-2029
4.1.1. By Value (USD Million)
4.2. Market Share & Forecast
4.2.1. By Testing Type
4.2.1.1. Conventional Testing
4.2.1.2. Non-conventional Testing
4.2.1.2.1. Fluorescence in-situ hybridization (FISH)
4.2.1.2.2. Immunohistochemistry (IHC)
4.2.1.2.3. Polymerase chain reaction (PCR)
4.2.1.2.4. Next-generation sequencing (NGS)
4.2.2. By Cancer Type
4.2.2.1. Prostate
4.2.2.2. Breast
4.2.2.3. Endometrial
4.2.2.4. Lung
4.2.2.5. Brain
4.2.2.6. Others
4.2.3. By End User
4.2.3.1. Hospitals
4.2.3.2. Pharmaceutical & Biotechnology Companies
4.2.3.3. Contract Research Organizations
4.2.3.4. Academic Research Institutes
5. Competitive Landscape
5.1. List of Key Players and Their Range
5.2. United States Solid Tumor Testing Company Market Share Analysis, 2022
5.3. Competitive Benchmarking, By Operating Parameters
5.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)
6. Impact of Covid-19 on United States Solid Tumor Testing Market Industry
7. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook, SWOT Analysis)
7.1. Agilent Technologies
7.2. Roche Diagnostics
7.3. QIAGEN
7.4. Thermo Fisher Scientific
7.5. Illumina, Inc.
7.6. PerkinElmer
7.7. Hologic
7.8. Bio-Rad Laboratories
7.9. Agios Pharmaceuticals
7.10. Guardant Health
7.11. Other Prominent Players
8. Key Strategic Recommendations
9. Research Methodology
9.1. Qualitative Research
9.1.1. Primary & Secondary Research
9.2. Quantitative Research
9.3. Market Breakdown & Data Triangulation
9.3.1. Secondary Research
9.3.2. Primary Research
9.4. Breakdown of Primary Research Respondents
9.5. Assumption & Limitation
*Financial information in case of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable.